Diamyd Medical increases investment in stem cell activity

Diamyd Medical (Nasdaq Stockholm First North Ticker: DMYD B) announced today that the Company invests an additional SEK 0.8 million in Cellaviva AB, Sweden's first commercial biobank for stem cells.Diamyd Medical’s investment of SEK 0.8 million in Cellaviva AB is made in connection with Mabtech AB buying into Cellaviva in an issue totaling SEK 6 million together with other shareholders prior to the introduction of Cellaviva’s first product; collection and storage of umbilical cord blood stem cells, where parents are given the opportunity to save stem cells from their newborn child. The